OR WAIT null SECS
August 19, 2021
Merck KGaA has partnered with Telix Pharmaceuticals to conduct combination clinical studies for cancer therapy.
The collaboration will focus on the interactions between WTX-124 indukine and KEYTRUDA (pembrolizumab).
A new method developed by the NIH bypasses genetic RNA extraction, simplifying the testing process.
August 18, 2021
WHO’s solidarity plus trial will enroll hospitalized patients to test artesunate, imatinib, and infliximab in hospitalized COVID-19 patients.
Lilly’s insulin, lyumjev, receives FDA approval for an expanded label.
The Cleveland, Ohio facility will produce critical anti-infective drug products for US hospitals.
Artiva Biotherapeutics’s new R&D and GMP manufacturing center in San Diego, Calif., for NK cell therapies is expected to open in 2022.
August 17, 2021
Primates inoculated with CV2CoV show improved immune response and protection from various COVID variants.
August 13, 2021
Terumo Blood and Cell Technologies and PhotonPharma announced a collaboration to develop a novel tumor-specific immunotherapy for solid tumors.
PNI expands global headquarters with a new 75,000-square-foot facility, which will include multiple GMP suites for manufacturing RNA therapeutics and vaccines.